KPWS
ALNY icon

Kestra Private Wealth Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kestra Private Wealth Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$247K Buy
+822
New +$248K ﹤0.01% 1587
2025
Q4 		– Sell
-504
Closed -$230K – 1728
2025
Q3 		$230K Buy
+504
New +$205K ﹤0.01% 1499

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kestra Private Wealth Services's ALNY Position: Q2 2026 in Review

Kestra Private Wealth Services opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 822 shares worth $247K. The stake represents ﹤0.01% of the portfolio and ranks #1587 among its holdings. This is a return to the name: Kestra Private Wealth Services previously reported a position in ALNY as recently as Q3 2025.

Kestra Private Wealth Services first reported a position in ALNY in Q3 2025 and has held it in 2 quarters since. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Kestra Private Wealth Services held 822 shares of Alnylam Pharmaceuticals worth $247K as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Kestra Private Wealth Services position in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Kestra Private Wealth Services's portfolio in Q2 2026, its #1587 holding.
  • Kestra Private Wealth Services first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Kestra Private Wealth Services's 13F filing for Q2 2026, filed 28 Jul 2026.